<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560716</url>
  </required_header>
  <id_info>
    <org_study_id>CYC116-06-01</org_study_id>
    <nct_id>NCT00560716</nct_id>
    <nct_alias>NCT00530465</nct_alias>
  </id_info>
  <brief_title>A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclacel Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclacel Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced
      solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">November 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>over the course of study</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Solid Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYC116</intervention_name>
    <description>Dose escalation of CYC116</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Incurable advanced solid tumors that did not respond to conventional therapy or for
             which no effective therapy exists

          -  Age &gt;=18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Life expectancy â‰¥ 3 months

          -  Evaluable disease

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate liver function

          -  At least 3 weeks from prior systemic treatments including investigational anti-cancer
             therapy, radiation therapy; and have recovered from prior toxicities

          -  Able to swallow capsules

          -  At least 3 weeks from major surgery

          -  Agree to practice effective contraception

        Exclusion Criteria:

          -  Previously untreated CNS metastasis or progressive CNS metastasis documented by MRI
             scan performed at 4 weeks or longer after the last treatment for CNS metastasis

          -  Currently receiving radiotherapy, biological therapy, or any other investigational
             agents

          -  Uncontrolled intercurrent illness

          -  Pregnant or lactating women

          -  Known to be HIV-positive

          -  Known active hepatitis B and/or hepatitis C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy H Chiao, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cyclacel Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2007</study_first_submitted>
  <study_first_submitted_qc>November 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>October 21, 2009</last_update_submitted>
  <last_update_submitted_qc>October 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Judy H. Chiao, M.D., VP of Clinical Development and Regulatory Affairs</name_title>
    <organization>Cyclacel</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

